Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI (R) (lecanemab) for Early Alzheimer's Disease TOKYO and CAMBRIDGE, Mass., September 8, 2026 - (JCN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results